PMV Pharma Announces Proposed Public Offering of Securities
Rhea-AI Summary
PMV Pharma (Nasdaq: PMVP) has commenced an underwritten public offering of its common stock with accompanying warrants, and pre-funded warrants with accompanying warrants for certain investors. All securities in the proposed offering will be sold by PMV Pharma. TD Cowen is the sole book-running manager, and the transaction is being conducted under an effective shelf registration statement on Form S-3. Completion, timing, size and final terms of the offering remain subject to market and other conditions.
Positive
- Underwritten equity and warrant offering may provide new capital to PMV Pharma
- All offered securities are primary, directing proceeds to PMV Pharma rather than selling shareholders
- Effective Form S-3 shelf registration supports timely access to public capital markets
Negative
- Equity and warrant issuance will dilute existing PMVP shareholders, though exact level is undisclosed
- Accompanying warrants and pre-funded warrants may create future share overhang and additional dilution risk
News Explained
No offering amount or final terms are set, so proceeds and dilution remain unquantified despite the commencement announcement.
The offering has commenced, but PMV has not disclosed its size, final terms, or completion; proceeds and dilution to existing common holders therefore remain unquantified.
An S-3 shelf provides capacity for future registered sales rather than selling shares itself, while the underwritten structure involves a bank buying and reselling securities, with fees reducing net proceeds.
As of
The company says a preliminary prospectus supplement describing the offering terms will be filed; completion remains subject to market and other conditions.
Sources and calculations
- PMV Pharma proposed public offering announcement (2026-08-31)
- Dilution definition (2026-07-17)
- Underwritten offering definition (2026-07-17)
- Form S-3 purpose (2026-07-17)
- PMV Pharmaceuticals second-quarter 2026 fundamentals (2026-06-30)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate ($12,469,000 + $66,962,000) / ($14,577,000 / 91) = 495.9 days
Market reaction after public offering of securities: PMVP -20.58%
Following this news, PMVP has declined 20.58%, reflecting a significant negative market reaction. Argus tracked a trough of -55.4% from its starting point during tracking. Our momentum scanner has triggered 15 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.96. Trading volume is above average at 1.9x the average, suggesting increased trading activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 14 | Second-quarter results | Positive | +4.5% | Completed primary-analysis enrollment and reiterated Q1 2027 NDA plan |
| May 12 | First-quarter results | Positive | +2.2% | Reported Orphan Drug Designation and Phase 2 ovarian-cancer activity |
| Apr 22 | Board chair transition | Neutral | +1.4% | Announced Laurie Stelzer's incoming board-chair role |
| Mar 06 | Full-year results | Positive | +7.2% | Reported Phase 2 activity and planned Q1 2027 NDA |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history showed positive reactions to earnings updates, while the neutral board-chair transition also preceded a gain, creating one sentiment/reaction divergence.
Key Terms
underwritten public offering financial
pre-funded warrants financial
shelf registration statement regulatory
book-running manager financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by PMV Pharma. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TD Cowen is acting as the sole book-running manager for the proposed offering.
The securities described above are being offered by PMV Pharma pursuant to a shelf registration statement on Form S-3 (Registration No. 333-283349), as filed with the U.S. Securities and Exchange Commission (“SEC”) on November 20, 2024 and declared effective by the SEC on November 27, 2024. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may also be obtained, when available, from: TD Securities (USA) LLC, by mail at c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53. TP53 mutations are found in approximately half of all cancers. PMV Pharma is headquartered in Princeton, New Jersey.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to those related to the completion, timing, and size of the proposed public offering. While PMV Pharma believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the Company as well as certain estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in PMV Pharma’s filings with the SEC, many of which are beyond the Company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: whether or not the Company will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks and uncertainties which may be found in the section entitled “Risk Factors” in documents that the Company files from time to time with the SEC, including PMV Pharma’s Annual Report on Form 10-K for the year ended December 31, 2025 and PMV Pharma’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the registration statement and the preliminary prospectus supplement relating to the proposed public offering. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. PMV Pharma claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. PMV Pharma expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com
